TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35768939

Group type: EXPERIMENTAL
Intervention: Early Start (ES) with Glatiramer Acetate (GA)
Number of subjects: 208
Study: 33846735

Group type: COMPARATOR
Intervention: PAAPPAS-environment group (PEG)
Number of subjects: 2511

Group type: COMPARATOR
Intervention: PAAPPAS group (PG)
Number of subjects: 2511
Study: 36789634

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (200/50 mg) under fasted conditions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (200/50 mg) under fed conditions
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (fasted state)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (fed state)
Number of subjects: 72
Study: 33682060

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training in 20 °C (n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Aerobic exercise training in 33 °C (n=12)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training in 20 °C
Number of subjects: 21

Group type: COMPARATOR
Intervention: Aerobic exercise training in 33 °C
Number of subjects: 21
Study: 32286507

Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old therapy
Number of subjects: 0
Study: 36127096

Group type: EXPERIMENTAL
Intervention: Exercise and patient education
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 34059094

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks) with UV1 vaccine (8 intradermal injections during the first three months)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab
Number of subjects: 118
Study: 36068002

Group type: EXPERIMENTAL
Intervention: Intralesional collagenase Clostridium histolyticum (CCH) injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intralesional verapamil (ILV) injections
Number of subjects: 50
Study: 33479386

Group type: EXPERIMENTAL
Intervention: Cissus Quadrangularis (CQ) extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pioglitazone (PPAR-γ agonist)
Number of subjects: 0
Study: 36013512

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate 50 mg/kg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate 30 mg/kg
Number of subjects: 86
Study: 32192467

Group type: EXPERIMENTAL
Intervention: Zinc sulfate syrup (1 cc/Kg containing 5 mg/5 cc zinc sulfate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo syrup (1 cc/Kg sucrose)
Number of subjects: 60
Study: 35534904

Group type: EXPERIMENTAL
Intervention: REACH VN intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 350
Study: 33689524

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomization with adaptive clip method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utility approach for randomization procedure selection
Number of subjects: 0
Study: 35113046

Group type: EXPERIMENTAL
Intervention: EFV-based ART
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Participants with PDR
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Participants without PDR
Number of subjects: 207
Study: 34462887

Group type: EXPERIMENTAL
Intervention: HA-HL (high and low molecular weight hyaluronic acid formulation)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: HA-HL
Number of subjects: 692
Study: 35395276

Group type: EXPERIMENTAL
Intervention: Dose escalation (DE: 77Gy/35fx) to hypoxic volumes (HV)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard radiotherapy (ST: 70Gy/35fx)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-hypoxic tumors treated with standard radiotherapy (ST: 70Gy/35fx)
Number of subjects: 53
Study: 34684481

Group type: EXPERIMENTAL
Intervention: Increased protein intake to 1.7 g/kg body weight/d (New Zealand study, 10 weeks intervention)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Increased protein intake to 1.54 g/kg body weight/d (Austrian study, 6 weeks intervention)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Seasonal-based time effect observed in the Austrian study
Number of subjects: 148
Study: 32386040

Group type: EXPERIMENTAL
Intervention: Myofascial trigger point electroacupuncture therapy combined with solifenacin succinate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Solifenacin succinate
Number of subjects: 40
Study: 34236503

Group type: EXPERIMENTAL
Intervention: Array-RQMC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary Monte Carlo
Number of subjects: 0
Study: 32773226

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (pitavastatin + ezetimibe)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Standard lipid-lowering therapy (pitavastatin monotherapy)
Number of subjects: 880
Study: 35719228

Group type: EXPERIMENTAL
Intervention: Vibration Foam Rolling (VFR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 34312204

Group type: EXPERIMENTAL
Intervention: StandingTall programme
Number of subjects: 400
Study: 32212801

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg once daily for at least 7 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (1 tab once daily for at least 7 days)
Number of subjects: 49
Study: 33410912

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 197

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 197
Study: 34687635

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily or 2.5 mg twice daily)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Avoid anticoagulation (oral antiplatelet agents could be prescribed)
Number of subjects: 101
Study: 36475824

Group type: EXPERIMENTAL
Intervention: Flexible Assertive Community Treatment (FACT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 131
Study: 33595776

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32150649

Group type: EXPERIMENTAL
Intervention: CMD (chlorambucil, mitoxantrone and dexamethasone)
Number of subjects: 400

Group type: COMPARATOR
Intervention: FMD (fludarabine, mitoxantrone and dexamethasone)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: CMD
Number of subjects: 400

Group type: COMPARATOR
Intervention: FMD
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Molecular negativity (both CMD and FMD)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: MRD negative patients (both CMD and FMD)
Number of subjects: 400
Study: 36163929

Group type: EXPERIMENTAL
Intervention: Asciminib 80mg once daily (QD)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Investigator-selected TKI (imatinib, bosutinib, dasatinib, or nilotinib at their approved doses)
Number of subjects: 69
Study: 33604379

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram incorporating Rad-score and clinical risk factors
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 80
Study: 36192125

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT) in military intervention group
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT) in nonmilitary intervention group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Military control group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Nonmilitary control group
Number of subjects: 133
Study: 32764089

Group type: EXPERIMENTAL
Intervention: High schools High on life intervention
Number of subjects: 16
Study: 34039560

Group type: EXPERIMENTAL
Intervention: Residual subretinal fluid (SRF) at month 3
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Residual SRF of any thickness (>0-50 μm, >50-100 μm, >100 μm)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Treatment-resistant subretinal fluid (TR-SRF)
Number of subjects: 785

Group type: COMPARATOR
Intervention: No residual SRF
Number of subjects: 785
Study: 33414066

Group type: EXPERIMENTAL
Intervention: Outpatient hospitalisation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Inpatient hospitalisation
Number of subjects: 160
Study: 34032505

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (41 subjects)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GnRH agonist (39 subjects)
Number of subjects: 80
Study: 34405742

Group type: EXPERIMENTAL
Intervention: P044
Number of subjects: 66

Group type: COMPARATOR
Intervention: Forsteo®
Number of subjects: 66
Study: 33887244

Group type: EXPERIMENTAL
Intervention: ALIS plus GBT
Number of subjects: 336
Study: 35641862

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin oral administration (500 mg) in morbidly obese individuals (n=10)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin intravenous administration (400 mg) in morbidly obese individuals (n=10)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin oral (500 mg) followed by intravenous (400 mg) administration in non-obese individuals (n=8)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin pharmacokinetics in obese individuals
Number of subjects: 28
Study: 34663404

Group type: EXPERIMENTAL
Intervention: Avapritinib (selective kinase inhibitor); administered daily
Number of subjects: 38
Study: 32253046

Group type: EXPERIMENTAL
Intervention: Educational intervention provided to participants
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: No educational intervention (initial willingness)
Number of subjects: 156
Study: 34151831

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation stretching
Number of subjects: 64
Study: 33928896

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) consisting of child nutrition education plus family engagement through parental nutrition education, meal preparation and tasting
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Single component intervention (SCI) of child nutrition education
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 306
Study: 34230023

Group type: EXPERIMENTAL
Intervention: Structure-function (S-F) analysis combining spectral-domain optical coherence tomography (SD-OCT) and standard automated perimetry (SAP)
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP)
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT)
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Classification tree approach combining OCT, SAP and defect localisation data
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Structure-function (S-F) analysis
Number of subjects: 3001
Study: 32524231

Group type: EXPERIMENTAL
Intervention: Low-dose milk protein supplementation (10 g of milk protein daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Isocaloric placebo drink
Number of subjects: 122
Study: 32830553

Group type: EXPERIMENTAL
Intervention: Insulin infusion during euglycemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin infusion during hyperglycemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 0
Study: 35098970

Group type: EXPERIMENTAL
Intervention: Dasatinib plus quercetin
Number of subjects: 5
Study: 32981154

Group type: EXPERIMENTAL
Intervention: Internal jugular vein compression (JVC) using an externally worn neck collar
Number of subjects: 284

Group type: COMPARATOR
Intervention: Non-collar group (control)
Number of subjects: 284
Study: 32474696

Group type: EXPERIMENTAL
Intervention: Local intra-gestational sac methotrexate injection followed by dilation and curettage (D&C)
Number of subjects: 31
Study: 35793982

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) 750 mg daily for a month after EVAR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Tranexamic Acid (non-TA)
Number of subjects: 0
Study: 34167677

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted thrombolysis (USAT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard catheter-directed thrombolysis (SCDT)
Number of subjects: 81
Study: 32651132

Group type: EXPERIMENTAL
Intervention: Exergaming (interactive cycling during 6 months)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 112
Study: 36208563

Group type: EXPERIMENTAL
Intervention: Cross-suturing intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional suturing (control)
Number of subjects: 16
Study: 33430774

Group type: EXPERIMENTAL
Intervention: Early administration of a small amount of water immediately after recovery from general anesthesia.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group received a small amount of water at 4 to 6 hours after the operation.
Number of subjects: 300
Study: 32961681

Group type: EXPERIMENTAL
Intervention: Hippotherapy (30min sessions for 12 weeks, twice a week)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hippotherapy (30min sessions for 12 weeks, once a week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no hippotherapy)
Number of subjects: 45
Study: 35086102

Group type: EXPERIMENTAL
Intervention: Chronic intranasal oxytocin (OT) administered daily for 5 days or every other day
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 34553346

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5mg once daily for 4 to 6 weeks
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Rivaroxaban 10mg once daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Low molecular weight heparin (intermediate dose)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Both study arms (Fondaparinux and Rivaroxaban)
Number of subjects: 1000
Study: 33313718

Group type: EXPERIMENTAL
Intervention: Pushing Splints 3 (PS3) therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rapid maxillary expansion and facemask therapy (RME/FM)
Number of subjects: 48
Study: 33112550

Group type: COMPARATOR
Intervention: 4% formalin application
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Colonic water irrigation and oral antibiotics (metronidazole and ciprofloxacin)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Colonic water irrigation
Number of subjects: 34
Study: 35295073

Group type: EXPERIMENTAL
Intervention: Alogliptin-Pioglitazone (ALO-PIO)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Alogliptin (ALO)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Glimepiride (GLIM)
Number of subjects: 99
Study: 32846108

Group type: EXPERIMENTAL
Intervention: Advanced carbohydrate counting (ACC) and use of an automated bolus calculator (ABC)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Manual calculation of insulin bolus (MC)
Number of subjects: 79
Study: 34255075

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 minutes of moderate aerobic exercise)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (sitting and reading for 30 minutes)
Number of subjects: 92
Study: 32279887

Group type: EXPERIMENTAL
Intervention: Kane keratoconus formula
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: SRK/T
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Barrett Universal 2
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Unmodified Kane
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Holladay 1
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Unmodified Holladay 2
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Haigis
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Hoffer Q
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Holladay 2 with keratoconus adjustment
Number of subjects: 147

Group type: COMPARATOR
Intervention: Normal IOL formulas (Barrett Universal 2, Haigis, Hoffer Q, Holladay 1, Holladay 2, Kane, SRK/T)
Number of subjects: 147
Study: 35667959

Group type: EXPERIMENTAL
Intervention: REACH VN intervention (in‐home, multicomponent, family caregiver support intervention delivered over two to three months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced control group
Number of subjects: 60
Study: 34889153

Group type: EXPERIMENTAL
Intervention: Turkish classical music therapy (6 sessions, 10 minutes each)
Number of subjects: 60
Study: 34397423

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32070246

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) supplementation (8 μg/kg birthweight/day as a single daily dose)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 35411074

Group type: EXPERIMENTAL
Intervention: Psilocybin therapy (10 mg and 25 mg, orally administered, 7 days apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psilocybin therapy (2 × 25 mg, orally administered, 3 weeks apart, plus 6 weeks of daily placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram (2 × 1 mg, orally administered, 3 weeks apart, plus 6 weeks of daily escitalopram 10–20 mg)
Number of subjects: 0
Study: 34195900

Group type: EXPERIMENTAL
Intervention: Observation, sentinel lymph node biopsy, or elective neck dissection for management of the cN0 neck
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study: 32078337

Group type: EXPERIMENTAL
Intervention: 2 sessions/week REHIT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3 sessions/week REHIT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 4 sessions/week REHIT
Number of subjects: 42
Study: 33632018

Group type: EXPERIMENTAL
Intervention: Operational definitions of constructs (performance, achievement, success)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Measurement of job performance via self-rating indicators
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Use of GPA as a universal indicator of academic outcomes
Number of subjects: 262
Study: 34933978

Group type: EXPERIMENTAL
Intervention: Chamas for Change (community-based women's health education program)
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Standard of care (monthly home visits)
Number of subjects: 1273
Study: 34618479

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioral therapy (CA‐CBT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 23
Study: 34226737

Group type: EXPERIMENTAL
Intervention: FMT-LF
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FMT-HF
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: HF
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: LF
Number of subjects: 70
Study: 32334074

Group type: EXPERIMENTAL
Intervention: Active NBM DBS stimulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study: 35457291

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Self-monitoring (Control)
Number of subjects: 41
Study: 32598502

Group type: EXPERIMENTAL
Intervention: Dim light melatonin onset (DLMO) measurement
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Actigraphy measurement of sleep onset time
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Morningness-eveningness questionnaire (MEQ)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Light exposure and activity rhythms
Number of subjects: 73
Study: 34266855

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 139002

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in women
Number of subjects: 139002

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in men
Number of subjects: 139002

Group type: COMPARATOR
Intervention: Control group (adults without type 2 diabetes)
Number of subjects: 139002
Study: 32316984

Group type: EXPERIMENTAL
Intervention: LOCal Assessment and Triage Evaluation (LOCATE) model of care
Number of subjects: 234

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 234
Study: 33992297

Group type: EXPERIMENTAL
Intervention: Direct myofascial release (MFR) on the posterior thigh region
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo technique
Number of subjects: 68
Study: 32528340

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) psychotherapy plus prenatal usual care (PUC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prenatal usual care (PUC)
Number of subjects: 70
Study: 33563873

Group type: EXPERIMENTAL
Intervention: DWISTIR (short‐inversion time inversion‐recovery)
Number of subjects: 77

Group type: COMPARATOR
Intervention: DWISTIR+SSRF (spectral‐spatial RF)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DWISTIR and DWISTIR+SSRF
Number of subjects: 77
Study: 34849429

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg in 150 ml normal saline)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg in 150 ml normal saline)
Number of subjects: 185
Study: 32524424

Group type: EXPERIMENTAL
Intervention: Elevated efavirenz concentration (≥ 4.0 mg/L)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Switch to rilpivirine (after discontinuing efavirenz)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light (Nfl) levels
Number of subjects: 54
Study: 35463209

Group type: EXPERIMENTAL
Intervention: New radial artery hemostasis device (CD group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TR Band (TR group)
Number of subjects: 60
Study: 33299890

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg per day)
Number of subjects: 36
Study: 36001526

Group type: EXPERIMENTAL
Intervention: 1-week intensive trabeculectomy surgical simulation course
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study: 33720272

Group type: EXPERIMENTAL
Intervention: Standard OMT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 200
Study: 32492913

Group type: EXPERIMENTAL
Intervention: Monomeric and oligomeric flavanols (MOF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0